II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Sales/Maturities of Investments

Last Annual Value

9.80M

3-Year CAGR

-56%

5-Year CAGR

%

10-Year CAGR

%

II

ImageneBio Inc Competitors Analysis of Sales/Maturities of Investments

IMA · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
9.80M
-60.1%N/AN/A 
109.38M
-0.6%2.2%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
145.00M
N/A69.9%N/A
0.00
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
0.00
N/AN/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
0.00
N/AN/AN/A
0.00
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
40.00M
-18.2%47.7%1.4%
311.66M
-12.2%13.3%16.7%
42.00M
-29.5%N/AN/A
15.00M
N/A-43.6%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69